Search

everythinglearnresearchcommunity

for

Search:↓

Sintilimab with chemotherapy improves survival and response in advanced lung cancer but increases some side effects.

Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.

Tofacitinib helped improve symptoms and hair growth in a patient with Aicardi-Goutières syndrome.

Dabrafenib can cause skin growths and sometimes low-grade skin cancer.

Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.

Tofacitinib helped a woman regrow hair with no major side effects.

Tofacitinib helped a 19-year-old regrow hair after other treatments failed.

A cancer drug called nilotinib might cause hair loss due to inflammation around hair follicles.

Tofacitinib helped regrow hair in patients with alopecia, with few side effects.

Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.

PRMT5 inhibitors effectively fight adenoid cystic carcinoma in salivary glands.

Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.

Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

JAK inhibitors can be safely used for alopecia areata in patients with latent hepatitis B or stable tuberculosis with proper monitoring.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

Bendamustine combined with rituximab is an effective and well-tolerated treatment for certain types of lymphoma.

Sorafenib can cause a unique skin reaction.

JAK inhibitors can be safely used in alopecia areata patients with latent hepatitis B or tuberculosis, with proper monitoring.

The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.

Blocking mTORC1 reduces skin tumor growth in mice.

Primary care doctors need to monitor JAK and TYK-2 inhibitors carefully for skin conditions.

Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.

CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.

Ruxolitinib can help regrow hair in severe alopecia areata.

JAK inhibitors show promise for treating various skin diseases.

Upadacitinib may help regrow hair in children with alopecia areata and is generally safe.

Trodelvy™ helped some patients with advanced breast cancer, but had side effects.